Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A

Summary

Twenty six patients with mild or moderate haemophilia A and inhibitors are described. The inhibitor was detected at a median age of 33 years, after a median of 5.5 bleeding episodes. This usually following intensive replacement therapy. The median presenting inhibitor titre was antihuman 11.6 BU/ml, antiporcine 1.45 BU/ml. Plasma basal factor VIII level declined from a median of 0.08 IU/ml to 0.01 IU/ml following the inhibitor development. This caused spontaneous bleeding in 22 and a bleeding pattern similar to acquired haemophilia in 17. Bleeding was often severe and caused two deaths.

The inhibitor disappeared spontaneously, or following immune tolerance induction, in 16 cases after a median of 9 months (range 0.5-46), with a return to the original baseline VIIIC level and bleeding pattern accompanied inhibitor loss. The inhibitor persisted in the remainder of the cases over a median period of 99 months (range 17-433 months) of follow-up. Inhibitors are an uncommon complication of mild haemophilia which frequently persist and may be associated with severe, life-threatening, haemorrhage.

Forty-one percent of treated haemophilic family members had a history of factor VIII inhibitors, suggesting a familial predisposition to develop inhibitors in these kindreds. Sixteen patients from 11 families were genotyped. Seven different missense mutations affecting the light chain were detected and two in the A2 domain. Five patients from three families had a mutation causing a substitution of Trp²²²⁹ by Cys in the C2 domain which appears to predispose to inhibitor formation since 7 of the 18 affected individuals have a history of inhibitor development.

• References

• 1 Lusher JM, Arkin S, Abildgaard CF, Schwarz RS. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. N Eng J Med 1993; 328: 453-9.
• 2 Ehrenforth S, Kreutz W, Scharrer I, Linde R, Funk M, Gungor T. Incidence of development of factor VIII and IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
• 3 Addiego J, Kasper CK, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. The Lancet 1993; 342: 462-4.
• 4 Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Hack A, Olek K, Tuddenham EGD, Oldenberg J. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74 (06) 1402-6.
• 5 Sultan Y. and the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-2.
• 6 Rizza CR, Spooner RGD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. British Medical Journal 1983; 286: 929-32.
• 7 Beck P, Giddings JC, Bloom AL. Inhibitor of factor VIII in mild haemophilia. British J Haematol 1969; 17: 283-8.
• 8 Strauss HS. Acquired circulating anticoagulants in hemophilia A. N Eng J Med 1969; 281: 866-73.
• 9 Crowell EB. A factor VIII inhibitor in a mild hemophiliac. Am J Med Sci 1970; 260: 261-3.
• 10 Robboy SJ, Lewis EJ, Schun PH, Colman RW. Circulating anticoagulants to factor VIII. Am J Med 1970; 49: 742-52.
• 11 Lechner K, Ludwig E, Niesner H, Thaler E. Factor VIII inhibitor in a patient with mild hemophilia A. Haemostasis 1970; 1: 261-70.
• 12 Shapiro SS, Hultin M. Acquired inhibitors to blood coagulation factors. Seminars in Thromb Haemost 1975; 1: 336-85.
• 13 Lowe GDO, Harvie A, Forbes CD, Prentice CRM. Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor. Brit Med J 1976; 2: 1110-1.
• 14 Kesteven PJ, Holland LJ, Lawrie AS, Savidge GF. Inhibitor to factor VIII in mild haemophilia. Thromb Haemost 1984; 52 (01) 50-2.
• 15 Bovill EG, Burns SL, Golden EA. Factor VIII antibody in a patient with mild haemophilia. Brit J Haematol 1985; 61: 323-8.
• 16 Capel P, Toppet M, Van Remoortel E, Fondue P. Factor VIII inhibitor in mild haemophilia (letter). Br J Haematol 1986; 62: 786-7.
• 17 Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterisation and response to factor VIII and desmopressin. Thromb Haemost 1995; 74 (02) 619-21.
• 18 Kasper CK, Aledort LM, Counts RB, Edson JR, Frantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thrombosis et Diathesis Haemorrhagica 1975; 34: 869-72.
• 19 Rizza C, and Biggs R. The treatment of patients who have factor VIII antibodies. Br J Haematol 1973; 24: 65-82.
• 20 Naylor JA, Green PM, Montandon AJ, Rizza CR, Giannelli F. Detection of three novel mutations in two hemophilia A patients by rapid screening of the whole essential region of factor VIII. Lancet 1991; 337: 635-9.
• 21 Montandon AJ, Green PM, Giannelli F, Bentley DR. Direct detection of point mutations by mismatch analysis: application to haemophilia B. Nucleic Acid Res 1989; 17: 3347-58.
• 22 Green PM, Bentley DR, Mibashan RS, Nilsson IM, Giannelli F. Molecular pathology of haemophilia B. EMBO J 1989; 8: 1067-72.
• 23 United Kingdom Haemophilia Centre Directors Organisation.. Annual Returns for 1994. Copyright UKHCDO 1995.
• 24 Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with haemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Eng J Med 1988; 318: 947-50.
• 25 Mauser-Bunschoten EP, Niewenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
• 26 Brackmann HH, Oldenberg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years’ of the “Bonn Protocol”. Vox Sanguinis. 1996 70. (suppl. 1): 30-35.
• 27 Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurised factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
• 28 Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briet E, van den Berg HM. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised dutch concentrate compared to classical inhibitors in haemophilia A. Thromb Haemost 1994; 71 (06) 703-6.
• 29 Rosendaal FR. Factor VIII inhibitors on a SD-treated and pasteurised concentrate associated with specific batches and batch characteristics. Thromb Haemost. 1997 suppliment; 590.
• 30 Tuddenham EGD, Schwaab R, Seehafer J, Millar DS, Gitcher J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A, Peake IR, Olek K, Kazazian HH, Lavergne JM, Giannelli F, Antoniarakis SE, and Cooper DN. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Research 1994; 22: 3511-33.
• 31 Schwaab R, Ludwig M, Oldenburg J, Brackmann HH, Egli H, Kochhan L, Olek K. Identical point mutations in the factor VIII gene that have different clinical manifestations of haemophilia A. American J of Human Genetics 1990; 47: 743-744.
• 32 Fijnvandraat K, Turenhout EAM, van den Brink EN, ten Cate JW, Mouril JA, Peters M, Voorberg J. The missense mutation Arg593-Cys is related to antibody formation in a patient with mild haemophilia A. Blood 1997; 89: 4371-77.
• 33 Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 1992; 67: 665-9.
• 34 Scandella D, Mattingly M, Prescot R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralises human inhibitor antibodies that bind to A2. Blood 1993; 82: 1767-72-4.